GPhA Hosted Congressional Briefing on Proposed Prescription Labeling Changes

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 03-03-2014 15:56

The Generic Pharmaceutical Association (GPhA) hosted a Congressional briefing in late February to highlight its position on FDA's proposed rule on prescription labeling. The briefing for members of Congress and staff featured experts discussing the proposal, which calls for generic manufacturers to unilaterally change product labels, an action currently prohibited by law, according to GPhA.

“This proposal directly undermines the ‘sameness’ of generics and their brand counterparts —a fundamental scientific principle that is the very cornerstone of the success of generic medicines in the last thirty years,” said Gordon Johnston, former Deputy Director, FDA Office of Generic Drugs, in a press statement. “The proposed rule paves the way for different versions of safety information for the same products, undermining the important principle of consistency. Disregarding decades of regulatory stability in this way will create unwarranted confusion, raises patient safety concerns, and threatens the system that created thousands of affordable options for consumers.”

Alex Brill, Economist and CEO, Matrix Global Advisors, said, “By allowing label changes without prior FDA review and approval, the proposal will expose generic drug manufacturers to new liability that will drive up costs of generic drugs by at least $4 billion annually and, furthermore, may create confusion in the marketplace for patients, pharmacists and physicians. The resulting cost increase will be borne by both consumers in the form of higher insurance premiums and the government in the form of higher Medicare and Medicaid costs.”

A recent report by Matrix Global Advisors estimates that US healthcare costs would rise $4 billion annually if the proposed rule is enacted. Medicare and other government programs will incur $1.5 billion in annual new spending while private insurers and patients will pay $2.5 billion per year.

GPhA opposes the rule in its current form but continues to advocate for a multi-stakeholder collaboration to find a workable solution that does not undermine patient safety or access.

“Generic manufacturers stand ready to engage with the FDA in meaningful dialogue about how the proposed rule can be improved in a way that does not exceed FDA statutory authority or put patients at risk,” said Ralph G. Neas, President and CEO, GPhA, in the press statement.



Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription